Literature DB >> 21958719

Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes.

Namandjé N Bumpus1.   

Abstract

Chronic use of efavirenz (EFV) has been linked to incidences of hepatotoxicity in patients receiving EFV to treat HIV-1. While recent studies have demonstrated that EFV stimulates hepatic cell death a role for the metabolites of efavirenz in this process has yet to be examined. In the present study, incubation of primary human hepatocytes with synthetic 8-hydroxyEFV (8-OHEFV), which is the primary metabolite of EFV, resulted in cell death, caspase-3 activation and reactive oxygen species formation. The metabolite exerted these effects at earlier time points and using lower concentrations than were required for the parent compound. In addition, pharmacological inhibition of cytochrome P450-dependent metabolism of EFV using 1-aminobenzotriazole markedly decreased reactive oxygen species formation and cell death. Treatment of primary human hepatocytes with EFV and 8-OHEFV also stimulated phosphorylation of c-Jun N-terminal kinase (JNK) as well as phosphorylation of the JNK substrate c-Jun. Further, the mRNA and protein expression of an isoform of Bim (Bcl-2 interacting mediator of cell death) denoted as BimEL, which is proapoptotic and has been shown to be modulated by JNK, was increased. Inhibition of JNK using SP600125 prevented the EFV- and 8-OHEFV-mediated cell death. Silencing of Bim using siRNA transfected into hepatocytes also prevented cell death resulting from 8-OHEFV-treatment. These data suggest that the oxidative metabolite 8-OHEFV is a more potent inducer of hepatic cell death than the parent compound EFV. Further, activation of the JNK signaling pathway and BimEL mRNA expression appear to be required for EFV- and 8-OHEFV-mediated hepatocyte death.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958719     DOI: 10.1016/j.taap.2011.09.008

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  22 in total

Review 1.  Role of autophagy in alcohol and drug-induced liver injury.

Authors:  Jessica A Williams; Wen-Xing Ding
Journal:  Food Chem Toxicol       Date:  2019-12-23       Impact factor: 6.023

2.  Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

Authors:  Ronald J Ellis; Scott Letendre; Florin Vaida; Richard Haubrich; Robert K Heaton; Ned Sacktor; David B Clifford; Brookie M Best; Susanne May; Anya Umlauf; Mariana Cherner; Chelsea Sanders; Craig Ballard; David M Simpson; Cheryl Jay; J Allen McCutchan
Journal:  Clin Infect Dis       Date:  2013-12-18       Impact factor: 9.079

3.  Efavirenz and Efavirenz-like Compounds Activate Human, Murine, and Macaque Hepatic IRE1α-XBP1.

Authors:  Carley J S Heck; Allyson N Hamlin; Namandjé N Bumpus
Journal:  Mol Pharmacol       Date:  2018-11-15       Impact factor: 4.436

4.  Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.

Authors:  Lindsay B Avery; Jennifer L VanAusdall; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2012-11-19       Impact factor: 3.922

5.  8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.

Authors:  Maria Brandmann; Uwe Nehls; Ralf Dringen
Journal:  Neurochem Res       Date:  2013-10-04       Impact factor: 3.996

6.  Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.

Authors:  Christian Arend; Alica Rother; Stefan Stolte; Ralf Dringen
Journal:  Neurochem Res       Date:  2016-09-21       Impact factor: 3.996

7.  Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues.

Authors:  Elaine E To; Craig W Hendrix; Namandjé N Bumpus
Journal:  Biochem Pharmacol       Date:  2013-08-18       Impact factor: 5.858

8.  Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Authors:  Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

9.  Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice.

Authors:  Lindsay B Avery; Namandjé N Bumpus
Journal:  Mol Pharmacol       Date:  2013-10-08       Impact factor: 4.436

10.  Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.

Authors:  Julie M Lade; Lindsay B Avery; Namandjé N Bumpus
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.